Shares ofAnika Therapeutics Inc(NASDAQ:ANIK), a small-cap biotech focused on regenerativemedicine, were down 36% as of 11:10 a.m. EDT on Tuesday. The stock plummetedafter the company reported data from an important phase 3 study.
Headlines about Spherix (NASDAQ:SPEX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) jumped 11% in May, according to data provided byS&P Global Market Intelligence, after the biotech said it plans to test voclosporin, its only drug candidate, for additional diseases.
Aurinia is testing voclosporin in a phase 3 trial in patients with lupus nephritis that’s scheduled to complete....More>>>
America’s third biggest railroad company Norfolk Southern (NSC) reported earnings in the last week of April. The company presented another record quarter and was able to benefit from a trend that’s currently putting tremendous pressure on conventional transportation companies on the road. Overall I’m impressed and will continue to use Norfolk as my go-to railroad stock.
What a silly stock market. There I was on Tuesday at 2:00 p.m. waiting for the Dow Jones Industrial Average to crash 1,700 points as Trump verbally ripped Iran to shreds (and pulled out of the Iran deal). The Dow instantly tanked 80 points one sentence into Trump’s latest global spectacle. But then the Blue Chip index rallied back as Trump continued to hit Iran, and actually finished the....More>>>
In his annual shareholder letter, JPMorgan CEO Jamie Dimon pointed to data showing a radically shrinking U.S. stock market, echoing an increasingly common refrain on Wall Street and in corporate America. Dimon is working alongside business luminaries such as Warren Buffett, BlackRock’s Larry Fink and GM CEO Mary Barra to promote long-term stock market investment and regulations that will....More>>>
Last week’s best-performing penny stock was Cartesian Inc. (OTCMKTS: CRTN), a management consulting company that locked in an explosive gain of over 170%. That shows there’s still money to be made in stocks even as the market lost $768 billion last week, which is why we’re bringing you top penny stock to watch this week.
Last Wednesday (March 21), Cartesian stock rocketed....More>>>
Treasury yields slightly declined Monday, backing further away from the closely watched 3% level as investors looked ahead to the new Federal Reserve bosss first congressional testimony in hopes for clues on the pace of rate hikes.
Millions of Boomers are becoming senior citizens with 10,000 a day of us turning 65. A lot of us still have aging parents, now in their 80s, 90s and more. And by that age, a lot of these elders need some kind of help. Will it come from us, their aging adult children? All over this country, Boomer-aged adults are offering help whether physical or financial....More>>>
Shares of Gildan Activewear (TSE:GIL) (NYSE:GIL) have received a consensus rating of “Hold” from the eight research firms that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating. The average 12 month price targe
IBM Retirement Fund decreased its stake in American Tower Co. (NYSE:AMT) by 4.2% during the first quarter, Holdings Channel reports. The institutional investor owned 9,998 shares of the real estate investment trust’s stock after selling 437 shares during the quarter. IBM Retirement Fund&
From the movie "Coming To America." Source: Amazon.com
Gilead (NASDAQ:GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like Gilead would have the U.S. CAR-T market all to itself. However, Novarti
Celgene (CELG) has three key drugs in its late-stage pipeline and yet the market refuses to buy the stock. Bearishness is building up so much that the stock fell sharply on May 21. This continues the downtrend that began last year in Sept. 2017, when the stock traded at over $140 a share. The c
To stave off generic competition drug makers often get creative. They seek new uses for old drugs, seek patent extensions and refuse to provide samples to generic rivals. Allergan (AGN) even sold Restasis (dry eye) patents to the St. Regis Mohawks in order to rent their sov